Article
Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Cancer chemotherapy and pharmacology - 1 Jul 2022
Sechaud Romain, Sinclair Karen, Grosch Kai, Ouatas Taoufik, Pathak Dhrubajyoti
Abstract excerpt
PURPOSE: Midostaurin, approved for the treatment of newly diagnosed, FLT3-mutated acute myeloid leukemia (AML), is metabolized by cytochrome P450 3A4 (CYP3A4). Midostaurin with concomitant strong CYP3A4 inhibitors use (e.g., antifungal azoles) may result in drug-drug interactions. This post hoc a...
Topics
- Cytochrome P-450 CYP3A
- Cytochrome P-450 CYP3A Inhibitors
- Drug Interactions
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Staurosporine
- fms-Like Tyrosine Kinase 3